Elm Biotech

Elm Biotherapeutics is a biotechnology company focused on the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design bifunctional molecules and molecular glues that recruit the body's natural cellular machinery to eliminate disease-causing proteins. By targeting proteins previously considered "undruggable," Elm Biotherapeutics aims to create transformative treatments for patients with cancer and autoimmune disorders. The firm is part of the growing biotech ecosystem in New Haven, utilizing advanced chemical biology to optimize degrader potency and selectivity.